May 27, 2010
The Question
What is the cost-effectiveness of current monotherapies and prospective combinations for treating visceral leishmaniasis (VL) in Bihar, India?
What we found
Using cost per averted years of life lost and per death averted as measures, we find that available treatments for VL are cost-effective. Combinations tested are more effective than most monotherapies. Moreover, combinations and several treatment options increase the drugs life-span.
Why it matters
VL is a major burden in India, Bangladesh and Nepal. The countries are making a concerted effort to eliminate VL. Strategically, treatment cost-effectiveness is a key element.
